Can we predict tuberculosis cure? What tools are available?

Footnotes

• Conflict of interest: D. Goletti reports personal fees from Qiagen, Quidel and Janssen, outside the submitted work.

• Conflict of interest: C.S. Lindestam Arlehamn has nothing to disclose.

• Conflict of interest: T.J. Scriba reports two pending patents of blood transcriptomic signatures of risk.

• Conflict of interest: R. Anthony reports grants from FIND to study the utility of IP-10 for treatment monitoring, outside the submitted work.

• Conflict of interest: D.M. Cirillo reports an unrestricted grant from QIAGEN to research the use of Quantiferon plus to predict outcome, and grants from JANSSEN on the establishment of Bedaquiline DST as SRL, outside the submitted work.

• Conflict of interest: T. Alonzi has nothing to disclose.

• Conflict of interest: C.M. Denkinger reports that FIND is a non-for-profit foundation, whose mission is to find diagnostic solutions to overcome diseases of poverty in LMICs. It works closely with the private and public sectors and receives funding from some of its industry partners. It has organisational firewalls to protect it against any undue influences in its work or the publication of its findings. All industry partnerships are subject to review by an independent scientific advisory committee or another independent review body, based on due diligence, TTPs and public sector requirements. FIND catalyses product development, leads evaluations, takes positions, and accelerates access to tools identified as serving its mission. It provides indirect support to industry (e.g. access to open specimen banks, a clinical trial platform, technical support, expertise, laboratory capacity strengthening in LMICs) to facilitate the development and use of products in these areas. FIND also supports the evaluation of prioritised assays and the early stages of implementation of WHO-approved (guidance and PQ) assays using donor grants. In order to carry out test validations and evaluations, has product evaluation agreements with several private sector companies for the diseases FIND works in which strictly define its independence and neutrality vis-a-vis the companies whose products get evaluated, and describes roles and responsibilities.

• Conflict of interest: F. Cobelens has nothing to disclose.

• Support statement: The study was supported by grants from the European Union (643381-TBVAC2020-H2020-PHC-2014-2015), a grant from the National Institutes of Health of USA (NIH 1R21AI127133-01), funding from Italian Ministry of Health “Ricerca Finalizzata”: RF-2011-02349395 and from the Italian Ministry of Health (“Ricerca Corrente”). Funding information for this article has been deposited with the Crossref Funder Registry.